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Abstract. The safety and efficacy of amodiaquine (AQ), sulfadoxine-pyrimethamine (SP), and coadministered
AQ+SP was assessed in 351 Tanzanian children (age range, 6–59 months) with uncomplicated Plasmodium falciparum
malaria. This open, randomized study followed the 28-day World Health Organization (WHO) protocol and evaluated
safety using clinical and laboratory parameters. Children receiving SP were more likely to vomit during follow-up (32%
vs. 17%: P 0.03), and SP alone resulted in prolonged fever clearance times. Although Day 7 and Day 14 clinical and
parasitological cure rates were similar, by Day 28 45% of children treated with AQ demonstrated R1 resistance and
27.5% were clinical failures compared with 25% and 6.3%, respectively, for SP alone. Coadministered AQ+SP was safe,
combined the greater clinical (96.2%) and parasitological (64.2%) efficacy of SP with the more rapid symptom resolution
of AQ, and reduced the incidence of gametocytemia during follow-up (AQ+SP 12.6% vs. SP 29.9%; P  0.001). The
level of R1 resistance to SP may herald a rapid decline in its efficacy as SP drug pressure increases. Coadministration
of AQ+SP may delay this.
INTRODUCTION
Malaria kills approximately 1 million children every year,
most of them in sub-Saharan Africa.1 The mainstay of malaria
control remains early, effective treatment of clinical cases,2
yet the effectiveness of this policy is likely to decrease as
resistance to many of the available and affordable antima-
larial drugs increases. Resistance to chloroquine (CQ), a com-
mon first-line treatment for malaria in endemic countries, is
widespread and has been associated with an increase in mor-
tality.3 However, the decision to change antimalarial treat-
ment guidelines is complex; limited alternatives exist, and the
decision to change should take into consideration a large
number of variables, including the efficacy, cost, and avail-
ability of drugs, the public health impact of resistance, treat-
ment-seeking behavior, and the likely durability of the new
policy. The latter is largely determined by the rate at which
resistance to the first-line drug develops, itself a function of
the mechanisms of resistance.
There is considerable interest in the use of multiple drugs,
with different mechanisms of action, for the treatment of ma-
laria cases.4 Such combination treatment (CT) is likely to
extend the useful lifetime of the constituent drugs by reducing
the rate at which resistance develops. The “protection” of the
individual drugs is a function of the likelihood of a resistance-
conferring mutation arising at two (or more) relevant Plas-
modium falciparum gene loci and is very much lower than the
chance of a single mutation arising. CT may also have greater
efficacy than treatment with the individual drugs. Artemether
and its derivatives are advocated for inclusion in antimalarial
CT because they quickly reduce the level of parasitemia and
hence the parasite pool from which resistant P. falciparum
may arise.4 A number of trials are underway combining ar-
temether with existing antimalarials. Although early results
are promising,5 it is unclear how quickly artemether could be
made available at health facilities in sub-Saharan Africa and
at what cost.
Sulfadoxine-pyrimethamine (SP) is a readily available,
relatively cheap, and effective antimalarial. Tanzania has
joined Malawi and Kenya6,7 in replacing CQ with SP as first-
line treatment of malaria. However, concerns that the long
half-life of the drug may lead to a relatively rapid increase in
the rate at which resistance develops,8 especially in situations
in which the drug pressure is high, have been borne out by
molecular9 and in vivo studies10,11 and by the short duration
of its efficacy in Thailand.12 If SP is to be a useful component
of CT, it needs to be protected until combinations with arte-
mether are shown to be safe, effective, and available. Even a
rational combination of drugs will yield poor results if resis-
tance to one of the component drugs is high.
There has been renewed interest in amodiaquine (AQ) as
a malaria treatment in endemic settings.13 Because it is a
congener of chloroquine, cross-resistance may limit its effi-
cacy as a first-line antimalarial treatment.14 Nevertheless, it is
being considered as a second-line treatment in some coun-
tries.15
Anecdotal reports suggest that CQ and SP have been in-
creasingly coprescribed in areas of high CQ resistance16 de-
spite a lack of safety and efficacy data.17 If AQ and SP be-
come widely available, it seems likely that these too will be
coadministered. Both agents are associated with adverse re-
actions affecting the skin and bone marrow13,18 and it may be
that their combined use will produce an unacceptably high
rate of adverse events.
Because of the urgent need to protect SP and generate
safety data on AQ+SP, we undertook a three-arm, random-
ized, open-label safety and efficacy study of AQ, SP, and
AQ+SP in the treatment of uncomplicated P. falciparum ma-
laria in young Tanzanian children.
MATERIALS AND METHODS
Study area, population, and recruitment. The study was
conducted in the malaria holoendemic setting of Ifakara, situ-
ated in the rice-growing flood plains of the Kilombero River,
southern Tanzania, and described in detail elsewhere.19 Chil-
dren were recruited from the Mother and Child Health
(MCH) Clinic of the 380-bed St. Francis Designated District
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Hospital (SFDDH) between May and August 1999. Malaria is
the leading cause of pediatric admission and outpatient atten-
dances. A Day-7 parasitological chloroquine failure rate of
65% has been described in children aged 1–5 years.20 SP has
been available at health facilities for many years as a second-
line malaria treatment. AQ has not been readily available,
and there are no previous local efficacy estimates.
After verbal consent from the parent, permanent residents
of Ifakara between the ages of 6 months and 5 years present-
ing to the MCH Clinic with an axillary temperature  37.5°C
were screened for P. falciparum parasitemia. Those with an
asexual P. falciparum parasitemia of 2,000/L were eligible
for enrollment. The trial objective and procedures were ex-
plained in Kiswahili, and a series of questions were asked to
assess adequate comprehension. Written informed consent
was then requested from the guardians of all children before
recruitment to the study. Children were examined by a proj-
ect clinical officer, and demographic and clinical data were
recorded. Children were excluded if they were unable to tol-
erate oral medication or had any signs indicative of severe or
complicated malaria.21 Known chronic underlying disease
and sensitivity to trial medication were additional exclusion
criteria.
Randomization, treatment, and follow-up. Children were
randomly allocated to receive AQ, SP, or AQ+SP (all from
Shelys Pharmaceuticals, P.O. Box 3016, Pugu Rd, Dar es Sa-
laam, Tanzania) according to a computer-generated list of
treatments randomly assigned to study numbers in blocks of
nine. Envelopes marked with the study number contained a
piece of paper with the allocated treatment for that number
printed on it. Study numbers were allocated sequentially to
children as they presented. Children were issued with an iden-
tity card bearing their study number and other identification
information.
All antimalarial doses were given by a member of the re-
search team, the first dose at the MCH Clinic and the second
and third doses of AQ at the children’s homes. Dosages were
administered according to a weight-dosing schedule, which
ensured that the minimum dosages received were 25 mg/kg
for AQ (aiming to administer 10 mg/kg for Doses 1 and 2 and
5 mg/kg for Dose 3) and 25 mg/kg of sulfadoxine with 1.25
mg/kg of pyrimethamine. A replacement dose was given if
vomiting occured within 30 min of administration, and rescue
medication was given if there was vomiting of the replace-
ment dose. All children were given a single dose of paracet-
amol, 250 mg, 30 min before administration of the trial drug,
to control fever. Rescue medication consisted of nine doses of
quinine sulphate, 30 mg/kg/day, in line with the Tanzanian
National Treatment Guidelines, and was only given to chil-
dren with symptomatic parasitemia. Children who were para-
sitemic on Day 28 received one of the alternative treatment
regimens, regardless of fever, as recommended by WHO.21
Children were visited at home by a trained field worker 1,
2, 3, 14, and 21 days after recruitment. Children were asked to
return to the clinic for assessments on Days 7 and 28, and
mothers were encouraged to bring their child to the project
clinical officer at any time during follow-up if they were con-
cerned about the child’s well-being. At all contacts, including
admissions to the pediatric ward, standardized forms were
completed to facilitate the detection of any adverse events. A
symptom report form, based on the National Institutes of
Health common toxicity criteria, was completed at routine
follow-up visits when the axillary temperature was measured
and a blood slide and filter paper sample were collected for
later parasitological and molecular analysis, respectively. In
addition, capillary blood collected on Days 0 and 28 in a
microtainer was used to measure packed cell volume (PCV),
total and differential white cell counts, platelets, alanine
transaminase (ALT), -glutamyl transferase (-GT), and cre-
atinine as part of the safety assessment. The study protocol
was reviewed and approved by the Ifakara Health Research
and Development Centre’s Scientific and Ethical review com-
mittees.
Laboratory techniques. Field’s stain of thick blood films
was used to screen children before recruitment when 20 high-
power fields were examined. Thick films stained with Giemsa
were used for definitive parasite counts. A total of 200 thick
film fields were screened for non-falciparum Plasmodia, and
the number of asexual forms per 200 leukocytes were re-
corded and converted into parasite density per microliter by
assuming an average white cell count of 8,000/L. Gameto-
cytes were counted against 500 leukocytes. Hence, the limit of
detection of asexual forms was 40/L and for gametocytes
16/L. Each slide was read at least twice; a third reading was
performed for major discrepancies between the results of the
first two readings (either positive/negative discrepancies or a
ratio of the readings < 0.66 or > 1.33). The majority reading
for positive/negative discordances or the geometric mean of
three positive readings was taken as the definitive result.
PCVs were measured using a microhematocrit tube and mi-
crocentrifuge (Hawksley, Lancing, UK). Total and differen-
tial white cell counts were estimated using a semiautomated
Coulter-type counter (Sysmex 800, TOA Medical Electronics
Ltd, Kobe, Japan). Alanine transaminase (ALT), -GT, and
creatinine concentrations were measured using a multilayer
analizer (Vitros 250, Ortho-Clinical Diagnostics, Johnson &
Johnson). Electronic thermometers were used to measure ax-
illary temperature and were calibrated weekly using a water
bath and mercury thermometer.
Outcome measures, data management, and statistical meth-
ods. The safety profile was evaluated by documenting the
numbers and timing of deaths, admissions, and outpatient
attendances in study children. Particular attention was paid to
skin reactions and evidence of bone marrow suppression. The
proportions of children reporting symptoms absent at base-
line but developing during the course of follow-up were com-
pared to assess adverse drug effects. The proportion of chil-
dren with hematological and biochemical parameters falling
outside the normal range at Day 28 was also documented. The
efficacy of the different regimens in terms of resolution of
symptoms present at baseline was assessed by comparing the
total duration of symptoms in the different groups. All com-
parisons were made relative to SP because this is a standard
treatment.
Proportions of children with different levels of parasitologi-
cal resistance are presented at different times during follow-
up. Standard WHO clinical end points were used22: early
treatment failure (ETF), defined as the development of dan-
ger signs in the presence of parasitemia or severe malaria
during follow-up on Days 0, 1, 2, or 3, an axillary temperature
 37.5°C on Day 2 with parasitemia greater than Day 0,
axillary temperature  37.5°C on Day 3 with any parasitemia
or Day 3 parasitemia  25% of Day 0 parasitemia; late treat-
ment failure (LTF), defined as the development of danger
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signs in the presence of parasitemia or severe malaria during
follow-up on Days 4 to Day 28, without prior ETF or a tem-
perature  37.5°C in the presence of parasitemia during fol-
low-up on Days 4 to Day 28 without prior ETF; and adequate
treatment response (ATR), defined as the absence of para-
sitemia, irrespective of temperature, without previous ETF or
LTF or axillary temperature < 37.5°C, irrespective of parasit-
emia, without previous ETF or LTF, defined at each time
point (i.e., 3, 7, 14, 21, and 28 days).
Data were double entered into FoxPro (version 2.6) data-
bases, and discordances were resolved before range and con-
sistency checks were performed. Analysis was performed us-
ing Stata (version 5.0). Dichotomous outcomes were com-
pared using Pearson’s chi-square or Fisher’s exact test, as
appropriate. Mean values of normally distributed variables
were compared using Student’s t test. This sample size was
calculated to estimate failure rates to within 4.3% of a true
failure rate of 5% and to within 10% of a true failure rate of
50%.
RESULTS
A total of 361 children were randomized to receive AQ, SP,
or AQ+SP (Figure 1). Three children were subsequently
found to be younger than 6 months, and four had definitive
parasite counts less than 2000/L. Data from these children
were not included in the analyses. Baseline characteristics
(Table 1) and completeness of follow-up (see Figure 1) were
similar in all groups, although children receiving AQ alone
tended to be older than those receiving other treatments.
Overall, 35 (9.9%) children moved to the family farms during
follow-up, 56 (15.8%) failed to attend one or more follow-up
visits, and 15 (4.2%) were withdrawn for other reasons, in-
cluding two children who failed to receive a dose of AQ.
There were no significant differences in these reasons be-
tween the different groups.
Safety (Table 2).A 1-year old girl who received SP became
drowsy 6 h after recruitment and was admitted with an axil-
lary temperature of 38.5°C, Blantyre coma score of 4/5, and
mild dehydration. Convulsions shortly after admission were
controlled with diazepam, and she received intravenous qui-
nine. Her condition continued to deteriorate, and she died
FIGURE 1. Trial profile. Completeness of follow-up: AQ (n 91)
versus SP (n  79) versus AQ+SP (n  78): 2(2)  4.3, P  0.12.
Violate: missed a scheduled contact for reason other than requiring
rescue treatment.
TABLE 1
Baseline characteristics
Variable
Treatment group
AQ (n  118) SP (n  117) AQ + SP (n  119)
No. males (%) 47 (39.8%) 58 (49.6%) 59 (49.6%)
Mean age (years) 2.51 (2.28–2.73) 2.22 (2.01–2.43) 2.11 (1.89–2.33)
Mean PCV 29.2 (28.1–30.3) 28.6 (27.5–29.7) 29.4 (28.3–30.5)
No. with PCV < 25% (%) 23 (20.0) 27 (23.4) 22 (18.6)
Mean temperature (oC) 38.5 (38.3–38.7) 38.7 (38.5–38.9) 38.7 (38.5–38.9)
Mean weight (kg) 11.1 (10.7–11.6) 10.6 (10.1–11.1) 10.8 (10.1–11.4)
Parasite density (L) Geometric mean range
Mean 43,026 53,955 45,570
Range 2,542–399,960 2,236–399,960 2,068–399,960
Reported symptoms
History of fever (%) 116/117 (99.2) 115/115 (100) 118/119 (99.2)
Anorexia (%) 24/117 (20.5) 21/114 (18.4) 19/119 (16.0)
Vomiting (%) 34/117 (29.1) 32/115 (27.8) 25/119 (21.0)
Diarrhea (%) 5/117 (4.3) 3/116 (2.6) 3/119 (2.5)
Difficulty in breathing (%) 17/117 (14.5) 16/115 (13.9) 15/119 (12.6)
Lethargy (%) 9/117 (7.7) 7/115 (6.1) 9/119 (7.6)
Rash (%) 4/117 (3.4) 6/115 (5.2) 6/118 (5.1)
Unable to sit/stand as normal (%) 2/113 (1.8) 4/112 (3.6) 5/116 (4.3)
Figures in brackets are 95% confidence intervals unless otherwise specified.
AQ, amodiaquine; SP, sulfadoxine-pyrimethamine; PCV, packed cell volume.
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later the same day. The clinical assessment was a progression
of her clinical malaria rather than an adverse reaction to SP.
More children were admitted after treatment with AQ
alone than children treated with SP or AQ+SP. These admis-
sions tended to be later during the course of follow-up and
were mostly (14/16, or 87.5%) due to malaria. Hence, these
admissions reflect low efficacy of AQ rather than adverse
responses to the treatment. The total number of outpatient
attendances was similar in all groups, as was the frequency of
any skin rash. The 14 non-scabetic rashes were all asymptom-
atic macular-papular eruptions noticed incidentally at presen-
tation.
More children receiving SP reported vomiting during the
course of follow-up than children receiving AQ alone (see
Table 2). There was also a suggestion that children receiving
SP alone were more likely to give a history of breathing dif-
ficulties during the course of follow-up than children receiv-
ing AQ or AQ+SP. There were no significant differences in
the proportions of children with abnormal hematological or
biochemical test results on Day 28 (see Table 2).
Clinical efficacy (Table 3). Clinical outcomes in the three
groups were similar in the first 7 days of follow-up. There
were no late treatment failures in either the SP or AQ+SP
groups. However, there were a considerable number of late
treatment failures among children treated with AQ alone,
particularly after Day 14 and reaching 27% by the end of
follow-up. By Day 21 children treated with AQ+SP were sig-
nificantly less likely to require rescue medication than those
treated with AQ alone, and by Day 28 children treated with
SP alone were also significantly less likely to require rescue
medication than those in the AQ group. There were no dif-
ferences in the prevalence of severe anemia (PCV < 25%) at
the end of follow-up (AQ 3/80, SP 4/89, AQ+SP 3/94: 2 
0.2, P  0.9).
Children who received SP alone were significantly more
likely to be febrile (axillary temperature  37.5°C) at each
contact up to and including Day 7 (P < 0.01 at each contact;
Figure 2). By Day 21 children treated with AQ alone were
more likely to be febrile (5/77) than those treated with
AQ+SP (0/80; Fisher’s exact test P  0.027). Analysis of the
time taken for the other symptoms reported at recruitment
(see Table 1) to resolve suggested no other differences be-
tween the treatment regimens.
Parasitological efficacy (Table 4). None of the 13 ETFs ful-
filled criteria for R1–3 resistance and were excluded from the
analysis of parasitological efficacy. In the remainder, the rate
of parasite clearance was similar in the three groups over the
first 3 days (see Figure 3), although children who received SP
TABLE 3
Cumulative clinical failure rates
Day AQ SP AQ+SP
1–3 5/111 5/108 3/111
7 6/107 5/101 3/103
14 9/97 5/89 3/88
21 18/91* 5/81* 3/83
28 25/91† 5/79† 3/78
AQ, amodiaquine; SP, sulfadoxine-pyrimethamine.
* 2  6.85, P  0.009
† 2  13.01, P  0.0003.
TABLE 2
Safety evaluation
Variable AQ (n  118) SP (n  117) AQ + SP (n  119)
Clinical
Death 0 1 0
Total admissions 16 10 6
Mean follow-up day admitted 14.0 11.4 10.6
Total outpatient visits 42 50 43
Rash 6 5 7
Numbers developing new symptoms* (%)
Anorexia 41/93 (44.1) 41/93 (44.1) 47/100 (47.0)
Vomiting† 14/83 (16.9) 27/83 (32.5) 29/94 (30.8)
Diarrhea 38/112 (33.9) 32/113 (28.3) 28/116 (24.1)
Breathing problems‡ 9/100 (9.0) 17/99 (17.2) 10/104 (9.6)
Lethargy 39/108 (36.1) 33/108 (30.6) 24/110 (21.8)
Rash 6/113 (5.3) 4/109 (3.7) 5/112 (4.5)
Convulsions 0/117 0/116 1/119 (0.8)
Unable to sit/stand as normal 14/111 (12.6) 15/108 (13.9) 8/111 (7.2)
Hematology§ (%)
Total leukocytes < 5,000/L 3/81 (3.7) 3/90 (3.3) 2/94 (2.1)
Lymphocytes < 4.0 29/81 (35.8) 26/90 (28.9) 19/94 (20.2)
Neutrophils < 1.5 2/81 (2.5) 1/90 (1.1) 2/94 (2.1)
Platelets < 100 3/81 (3.7) 6/90 (6.7) 5/94 (5.3)
PCV < 33% 29/81 (35.8) 30/90 (33.3) 23/94 (24.5)
Biochemistry¶
ALT > 40 2/66 (3.0) 1/72 (1.4) 1/81 (1.2)
-GT > 40 4/59 (6.8) 1/60 (1.7) 1/71 (1.4)
Creatinine > 130 0/71 (0) 0/77 (0) 0/84 (0)
AQ, amodiaquine; SP, sulfadoxine-pyrimethamine; PCV, packed cell volume; ALT, alanine transaminase; -GT, -glutamyl transferase.
* Denominators for symptom reports are number of children without the symptom at recruitment.
† 2 6.3, P  0.04 (AQ vs SP).
‡ 2 2.9, P  0.08 (AQ vs SP).
§ Haemtaology cut-off values taken from Practical Haematology, Danci JV & Lewis SM, 8th Ed, 1995, Churchill Livingstone.
¶ Biochemistry cut-off values provided by biochemistry laboratory.
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alone were significantly less likely to be parasitemic on Day 2
than children in the other groups (P < 0.01). Overall levels of
R-I resistance were considerably higher in children treated
with AQ than in those receiving the other treatments, al-
though the level of R-I resistance to SP is notable.
Only three children were gametocytemic at recruitment
(AQ 1, AQ+SP 2). Of the 77 children with a PCV < 25%
at recruitment, 24 (31.2%) became gametocytemic compared
with 12 (11.1%) of the 108 children with a PCV 33% at this
time (2  11.4, P  0.003). In comparison with children
receiving AQ+SP, those treated with SP alone were more
likely to be gametocytemic during follow-up, and these ga-
metocytes tended to arise later during the course of follow-up
(see Figure 4).
DISCUSSION
We have documented the safety and efficacy of AQ, SP,
and AQ+SP in the treatment of uncomplicated P. falciparum
malaria in young children in southern Tanzania. The study
was based on the standard WHO in vivo test protocol with
follow-up to 28 days. The number of children lost to follow-up
and the reason-specific rates were comparable between the
groups. Treatment with AQ alone produced good parasito-
logical (78%) and clinical (94%) responses in the first 7 days
and was associated with a shorter fever clearance time than
SP alone. However, by the end of follow-up, AQ-only recipi-
ents were subject to a markedly higher level of R-I type re-
sistance than children in the other treatment groups and were
at least five times more likely to require rescue medication.
These findings are striking in an area where AQ has not
previously been readily available but where a 7-day parasito-
logical cure rate of only 35% was documented for CQ.20 Con-
cerns over cross-resistance between CQ and AQ seem to be
legitimate, although the results of molecular studies will be
needed to distinguish recrudescences from reinfections. Inter-
estingly, anecdotal reports during the trial suggested that the
faster symptom resolution associated with AQ gave an im-
pression of it being a “stronger” drug, and mothers specifi-
cally requested retreatment with AQ. Such perceptions could
be an important factor in the successful implementation of
treatment policies.23
The only death in the study cohort was a child who received
SP alone and was due to progression of the malarial disease.
It is not possible to say whether treatment with a faster-acting
antimalarial would have altered the outcome for this child.
Although the overall clinical cure rate for SP was good
(94%), it was associated with more vomiting than AQ alone
and its slower onset of action was reflected by a prolonged
FIGURE 3. Resolution of parasitemia over Days 1–3. Day 2: SP
29.9% (32/107) versus AQ 51.4% (56/109) 2  10.3, P  0.001.
FIGURE 4. Gametocyte prevalence during follow-up. AQ versus
SP: 2  2.9, P  0.09. SP versus SP+AQ: 2  10.6, P  0.001.
TABLE 4
Proportion of parasitological failures at days 7, 14, 21, and 28
Variable Sensitive R-I R-II
Day 7
AQ (n  103) 80 (77.7%) 6 (5.8%) 17 (16.5%)
SP (n  99) 74 (74.8%) 13 (13.1%) 12 (12.1%)
AQ + SP (n  102) 84 (82.4%) 9 (8.8%) 9 (8.8%)
Day 14
AQ (n  97) 66 (68.0%) 14 (14.4%) 17 (17.5%)
SP (n  90) 62 (68.9%) 16 (17.8%) 12 (13.3%)
AQ + SP (n  89) 68 (76.4%) 12 (13.5%) 9 (10.1%)
Day 21
AQ (n  95) 46 (48.4%) 32 (33.7%)* 17 (17.9%)
SP (n  84) 54 (64.3%) 18 (21.4%)* 12 (14.3%)
AQ + SP (n  84) 60 (71.4%) 15 (17.9%) 9 (10.7%)
Day 28
AQ (n  97) 36 (37.1%) 44 (45.4%)† 17 (17.5%)
SP (n  82) 49 (59.8%) 21 (25.6%)† 12 (14.6%)
AQ + SP (n  81) 52 (64.2%) 20 (24.7%) 9 (11.1%)
AQ, amodiaquine; SP, sulfadoxine-pyrimethamine.
* P  0.002.
† P  0.038.
FIGURE 2. Fever clearance time.
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fever clearance time. The parasitological profile after treat-
ment with SP is also cause for concern. An R-I resistance level
of 26% and an R-II level of 15% are bad news at a time when
SP drug pressure is likely to increase dramatically as a result
of the change in the national malaria treatment policy. Based
on experience from elsewhere,10–12 it is likely that clinical
resistance to SP will develop rapidly. This is of particular
concern because several studies of CT include SP as a con-
stituent drug; consequently, it may be that by the time SP-
containing CT regimens are available, their effectiveness will
have been undermined by increased levels of SP resistance.
More importantly, approaches to malaria control that require
long half-life drugs, such as intermittent treatment in in-
fants,24 may also be compromised.
The coadministration of AQ+SP appeared to combine the
rapid symptomatic relief associated with AQ with the greater
longer-term efficacy of SP. However, it is not clear whether
regular use of antipyretics during the first 2–3 days after pre-
sentation would be as effective in resolving symptoms as
treatment with amodiaquine. The clinical and parasitological
profiles after treatment with AQ+SP were similar to those
after treatment with SP alone.
Assessment of safety depended on data from outpatient
attendances, admissions to hospital, systematically collected
data on reported symptoms, and the results of hematological
and biochemical testing. More weight should be given to the
admission and outpatient department visit data than the re-
ported symptom data because the latter was more often un-
available for children who were admitted than for children
who were not, and these children were clearly more likely to
be symptomatic. The data presented are thus likely to under-
estimate the prevalence of symptoms in children receiving
only AQ. The higher rate of admission in the AQ-only group
reflected its antimalarial efficacy rather than adverse reac-
tions to the drug per se. Similarly, the increased tendency to
give a history of breathing difficulties in children who re-
ceived SP is likely to be a reflection of its slower onset of
action compared with AQ. Hence, no drug-related severe ad-
verse reactions were documented in any treatment group. It
was particularly reassuring that there was no suggestion of
increased frequencies of rash or bone marrow suppression in
children receiving AQ+SP.
Children who were anemic at baseline were more likely to
develop gametocytemia, in keeping with the findings from
another setting25 and presumably reflecting either a survival
strategy of P. falciparum or a longer period of P. falciparum
infection. Assuming the infectivity of gametocytes appearing
after treatment with SP is 40% and after AQ it is 60%,26 the
data suggest that treatment of 100 individuals with SP would
result in 12 infectious individuals compared with 13 with AQ
and 5 with AQ/SP. This extrapolation merits further investi-
gation through mosquito-feeding assays, although its rel-
evance to the intensity of transmission in an area would de-
pend on the malaria treatment rates in the group of individu-
als constituting the main reservoir of infection.
The evolution and dynamics of resistance to antimalarials
require new strategic thinking. Monotherapy with SP may not
be an optimal choice for first-line treatment of malaria in
endemic settings: the long half-life will tend to lead to the
development of resistance more rapidly than shorter half-life
drugs, reducing the effective life span of treatment policies
depending on it. However, as resistance to chloroquine in-
creases, National Malaria Control Programs are required to
implement policies with cheap, available, and effective anti-
malarial drugs: SP is one of a very few alternatives. We have
shown that significant levels of resistance to AQ exist in an
area historically devoid of AQ but with high levels of CQ
resistance, and that there are considerable levels of parasito-
logical resistance to SP. The combination of AQ+SP ap-
peared to be safe and combined the benefits of rapid symp-
tom relief with an improved parasitological response. An in-
terim policy in which AQ+SP was recommended would
combine the treatment benefits of the combination and might
reduce the rate at which SP resistance develops. Both AQ and
SP are readily available and thus not subject to the likely time
constraints of implementing a policy where SP is coadminis-
tered with artemether. Furthermore, these drugs are cheap; a
treatment course of AQ costs TSh 23 (U.S. $0.01) and a
course of SP about TSh 11.27,28 Finally, by reducing the rate
at which resistance develops to SP, coadministration of
AQ+SP may protect SP for use as intermittent treatment and
buy time while alternative, preferably short half-life, antima-
larial treatments are evaluated for inclusion alongside arte-
mether in malaria CT regimens.
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